Lung Cancer Dispatch
4.5K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

Combination of S-1, Platinol, and Radiation Promising for Lung Cancer

Combination of S-1, Platinol, and Radiation Promising for Lung Cancer | Lung Cancer Dispatch | Scoop.it

Results from a phase II clinical trial suggest that combining the cancer drug S-1 (Teysuno) with the chemotherapy agent cisplatin (Platinol) and radiation therapy may be effective in non-small cell lung cancer (NSCLC). Patients with inoperable, locally advanced NSCLC were treated with S-1, Platinol, and radiation to the chest region. Tumors shrank at least 30% in 36 out of 41 patients. Although some patients experienced low levels of white blood cells, overall the treatment was well tolerated. S-1 is itself a combination of tegafur (a chemotherapy agent), gimeracil (which boosts tegafur levels in the body), and oteracil (which protects the stomach and gut from tegafur toxicity).

Cancer Commons's insight:

Healio | Nov 8, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Combined Calsed and S-1 May be Effective Second-Line Treatment for Lung Cancer without EGFR Mutations

While new treatments for non-small cell lung cancer (NSCLC) such as tyrosine kinase inhibitors (TKIs) and Alimta (pemetrexed) are effective second-line treatments for patients whose tumors carry mutations in the EGFR gene, they are less effective for patients without such mutations. Twenty-six patients with inoperable, previously treated NSCLC received treatment with amrubicin (Calsed) and S-1 and experienced higher treatment response rates, longer periods without cancer progression, and longer overall survival than has been reported with single-agent chemotherapy. The beneficial effects were independent of cancer subtype, suggesting that combined Calsed and S-1 may be an effective second-line treatment for NSCLC without EGFR mutation.


Research paper: http://link.springer.com/article/10.1007/s00280-012-2061-1/fulltext.html

Cancer Commons's insight:

Cancer Chemotherapy and Pharmacology | Jan 18, 2013

more...
No comment yet.